CLDX Stock — Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc. (CLDX)

Updated October 16, 2026.

CLDX is a Stock. Total return is -96.9% over the past 40.4 years.

Celldex Therapeutics is a biopharmaceutical company developing therapeutic antibodies to treat severe inflammatory, allergic, autoimmune, and other diseases, with a focus on mast cell-mediated conditions where existing treatments are inadequate. The company does not currently distribute to shareholders. This security appeals to growth-oriented investors seeking exposure to early-stage drug development in immunology and inflammatory disease treatment.

CLDX performance

Price and return data through 2026-10-16.

Total return is -96.9% over the past 40.4 years. Over the past year its total return — price change plus distributions reinvested — is 3.7%. Its deepest 1-year drawdown was 38.6%.

CLDX key facts

Asset type

Stock

Asset class

Equity

Inception date

05/15/1986

Distribution frequency

None

Last close

$27.53 (as of 2026-10-16)

Market cap

$2,161,918,016

Average volume

997946.0

Payment date

02/11/2019

Beta

0.896

Payout ratio

0.0%

EPS

$-4.35

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CLDX risks and drawbacks

The deepest 1-year drawdown on record here is 38.6%.

Who may consider CLDX — and who may not

It is a weaker fit for investors who need monthly cash flow (CLDX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on CLDX

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions